Cargando…

A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains

BACKGROUND: Most currently approved anti-HIV drugs (e.g., reverse transcriptase inhibitors, protease inhibitors and fusion/entry inhibitors) must act inside or on surface of the target cell to inhibit HIV infection, but none can directly inactivate virions away from cells. Although soluble CD4 (sCD4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Lu, Pan, Chungen, Li, Yuan, Lu, Hong, He, Wu, Jiang, Shibo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3531269/ https://www.ncbi.nlm.nih.gov/pubmed/23217195 http://dx.doi.org/10.1186/1742-4690-9-104

Ejemplares similares

The Conserved Residue Arg46 in the N-Terminal Heptad Repeat Domain of HIV-1 gp41 Is Critical for Viral Fusion and Entry
por: Wang, Xiaoyi, et al.
Publicado: (2012)

HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions
por: Qi, Qianqian, et al.
Publicado: (2017)

HIV-1 prehairpin intermediate inhibitors show efficacy independent of neutralization tier
por: Bell, Benjamin N., et al.
Publicado: (2023)

A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells
por: Wang, Xinling, et al.
Publicado: (2022)

Rational Design of A Novel Small-Molecule HIV-1 Inactivator Targeting Both gp120 and gp41 of HIV-1
por: Pu, Jing, et al.
Publicado: (2021)

Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection
por: Wang, Xinling, et al.
Publicado: (2021)

Identification of a Human Protein-Derived HIV-1 Fusion Inhibitor Targeting the gp41 Fusion Core Structure
por: Chao, Lijun, et al.
Publicado: (2013)

Approaches for Identification of HIV-1 Entry Inhibitors Targeting gp41 Pocket
por: Yu, Fei, et al.
Publicado: (2013)

Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41
por: Pu, Jing, et al.
Publicado: (2019)

Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the prehairpin intermediate of the spike protein
por: Yang, Kailu, et al.
Publicado: (2022)

Induction of Antibodies in Rhesus Macaques That Recognize a Fusion-Intermediate Conformation of HIV-1 gp41
por: Dennison, S. Moses, et al.
Publicado: (2011)

HIV-1 Fusion Is Blocked through Binding of GB Virus C E2D Peptides to the HIV-1 gp41 Disulfide Loop
por: Eissmann, Kristin, et al.
Publicado: (2013)

Rational improvement of gp41-targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations
por: Zhu, Yun, et al.
Publicado: (2016)

Correction: HIV-1 Fusion Is Blocked through Binding of GB Virus C E2D Peptides to the HIV-1 gp41 Disulfide Loop
por: Eissmann, Kristin, et al.
Publicado: (2014)

HIV-1 gp41 Core with Exposed Membrane-Proximal External Region Inducing Broad HIV-1 Neutralizing Antibodies
por: Wang, Ji, et al.
Publicado: (2011)

The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects
por: Liu, Huan, et al.
Publicado: (2018)

Asymmetric Deactivation of HIV-1 gp41 following Fusion Inhibitor Binding
por: Kahle, Kristen M., et al.
Publicado: (2009)

HIV gp41-Mediated Membrane Fusion Occurs at Edges of Cholesterol-Rich Lipid Domains
por: Yang, Sung-Tae, et al.
Publicado: (2015)

Antiviral properties of two trimeric recombinant gp41 proteins
por: Delcroix-Genête, Delphine, et al.
Publicado: (2006)

Characterization of Gp41 Polymorphisms in the Fusion Peptide Domain and T-20 (Enfuvirtide) Resistance-Associated Regions in Korean HIV-1 Isolates
por: Jang, Dai-Ho, et al.
Publicado: (2014)

Modulation of Cytokine Release and Gene Expression by the Immunosuppressive Domain of gp41 of HIV-1
por: Denner, Joachim, et al.
Publicado: (2013)

DNA vaccines that express the MPER of HIV-1 gp41 elicit different antibodies depending upon their transmembrane and cytoplasmic domains
por: Scott, JK, et al.
Publicado: (2012)

Sub-Inhibitory Concentrations of Human α-defensin Potentiate Neutralizing Antibodies against HIV-1 gp41 Pre-Hairpin Intermediates in the Presence of Serum
por: Demirkhanyan, Lusine, et al.
Publicado: (2013)

Mutational analysis of HIV-1 gp41 mediated apoptosis and its correlation with fusion/hemifusion
por: Garg, Himanshu, et al.
Publicado: (2006)

Viroporin potential of the lentivirus lytic peptide (LLP) domains of the HIV-1 gp41 protein
por: Costin, Joshua M, et al.
Publicado: (2007)

Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein
por: Vassell, Russell, et al.
Publicado: (2015)

Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope
por: Penn-Nicholson, Adam, et al.
Publicado: (2008)

Antigenic and immunosuppressive properties of a trimeric recombinant transmembrane envelope protein gp41 of HIV-1
por: Mühle, Michael, et al.
Publicado: (2017)

Neutralizing Antibodies Targeting HIV-1 gp41
por: Caillat, Christophe, et al.
Publicado: (2020)

Site-specific Isopeptide Bridge Tethering of Chimeric gp41 N-terminal Heptad Repeat Helical Trimers for the Treatment of HIV-1 Infection
por: Wang, Chao, et al.
Publicado: (2016)

Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein
por: Joshi, Vinita R., et al.
Publicado: (2020)

A bivalent protein targeting glycans and HR1 domain in spike protein potently inhibited infection of SARS-CoV-2 and other human coronaviruses
por: Cai, Yanxing, et al.
Publicado: (2021)

The role of bivalent ions in the regulation of D-loop extension mediated by DMC1 during meiotic recombination
por: Altmannova, Veronika, et al.
Publicado: (2022)

3D6 and 4B3: Recombinant expression of two anti-gp41 antibodies as dimeric and secretory IgA
por: Reinhart, David, et al.
Publicado: (2011)

Characterization of HIV-1 envelope gp41 genetic diversity and functional domains following perinatal transmission
por: Ramakrishnan, Rajesh, et al.
Publicado: (2006)

Engineering Recombinant Reoviruses To Display gp41 Membrane-Proximal External-Region Epitopes from HIV-1
por: Boehme, Karl W., et al.
Publicado: (2016)

Biophysical Characterization of a Vaccine Candidate against HIV-1: The Transmembrane and Membrane Proximal Domains of HIV-1 gp41 as a Maltose Binding Protein Fusion
por: Gong, Zhen, et al.
Publicado: (2015)

Crystal Structure of HIV-1 gp41 Including Both Fusion Peptide and Membrane Proximal External Regions
por: Buzon, Victor, et al.
Publicado: (2010)

Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket
por: Zhang, Xiujuan, et al.
Publicado: (2018)

Novel screening systems for HIV-1 fusion mediated by two extra-virion heptad repeats of gp41
por: Nishikawa, Hiroki, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_3o4d9a7sd24k8lf8ot8grsjojb